

Lenalidomide Suspension 1.25 mg/mL

INGREDIENTS:

Lenalidomide 5 mg capsule	5 capsules
Sterile water for irrigation	QSAD: 20 mL

EQUIPMENT AND SUPPLIES:

Containment ventilated enclosure (CVE) or biological safety cabinet (BSC), graduated cylinder, beaker, hot plate, thermometer

PREPARATION DETAILS:

Caution: Hazardous Drug—Non-antineoplastic hazardous drug: Must be prepared in compliance with USP <800>.

1. Place capsules in a 30-mL oral syringe.
2. Add hot water (55°C) to the oral syringe.
3. Let mixture stand for 10 minutes.
4. Shake well to mix.

Quality-Control Procedures — Visually inspect for physical appearance of formulation and container closure integrity (no leakage, cracks in container, or improper seals).

Labeling Requirements — Extemporaneously compounded preparation. Caution: hazardous drug. For oral use only. Store at room temperature. Shake well before use.

Storage Conditions/Stability — Store at room temperature. Stable for 24 hours.

STABILITY STUDY DETAILS:

Study Container Type — Plastic syringe

Referenced Manufacturer — Lenalidomide capsules (Celgene Corp); sterile water for irrigation (not specified).

Stability-Indicating Study — No

REFERENCE

1. Morita TO, Yamaguchi A, Kimura S, et al. Stability of lenalidomide suspension after preparation by a simple suspension method for enteral tube administration. *J Oncol Pharm Pract.* 2016;22(4):579-583.